Acelrx pharmaceuticals inc (ACRX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Cash flows from operating activities:
Net loss

-53,240

-47,149

-51,508

-43,157

-24,399

-33,353

-23,426

-33,363

-20,101

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization

312

289

151

7

0

0

-

-

-

Non-cash interest (income) expense on liability related to royalty monetization

-1,337

10,341

10,721

9,382

2,428

0

-

-

-

Depreciation and amortization

1,668

575

1,744

2,052

1,984

866

593

605

513

Non-cash interest expense related to debt financing

712

613

1,265

877

897

-

-

-

-

Amortization of premium/discount on investments, net

-

-

-

-

-

-216

-202

-380

-195

Non-cash interest expense related to debt financing

-

-

-

-

-

553

442

647

1,619

Stock-based compensation

5,057

5,168

4,294

4,479

5,010

4,440

3,479

2,150

1,833

Revaluation of put option and PIPE warrant liabilities

-

-

-

-767

-2,136

-7,040

14,071

1,439

-1,512

Loss on extinguishment of debt

-

-

-

-

-

-

-1,202

-

-

Loss on disposal and impairment of property and equipment

-

-

-

-

-573

0

-

-

-

Inventory impairment charge

951

-

369

-

0

-

-

-

-

Other

773

201

198

-17

-114

-

-

-43

-

Revaluation of put option and PIPE warrant liabilities

-

-

-

-767

-2,136

-

-

-

-1,512

Changes in operating assets and liabilities:
Accounts receivable

383

-1,484

-4,300

2,547

3,286

0

-

-

-

Inventories

3,392

-102

-920

1,688

466

0

-

-

-

Prepaid expenses and other assets

465

850

-175

-975

783

-137

-1,132

-429

434

Restricted cash

-

-

-

-

-72

0

45

-

0

Tax receivable

-352

-

703

-

0

-

-

-

-

Other assets

220

-

-

-

-

-

-

-

-

Accounts payable

-19

458

309

-437

-786

90

106

705

987

Accrued liabilities

1,141

922

-1,301

639

325

-126

-760

2,029

1,788

Operating lease liabilities

-701

-

-

-

-

-

-

-

-

Deferred revenue

-219

-362

-361

989

-

-

-

-

-

Deferred revenue

-

-

-

-

784

-217

2,630

-

-

Deferred rent

-

113

360

-202

-284

-22

-113

354

-175

Net cash used in operating activities

-

-

-

-

-

-34,456

-487

-24,582

-

Net cash used in operating activities

-51,180

-29,075

-29,765

-29,395

-19,953

-

-

-

-15,287

Cash flows from investing activities:
Purchase of property and equipment

3,470

819

2,405

3,720

1,456

5,505

3,287

826

2,019

Purchase of investments

100,068

30,558

7,565

996

7,266

17,430

28,009

27,167

39,367

Proceeds from sales of investments

-

-

-

-

-

-

-

-

-2,082

Proceeds from maturities of investments

66,975

20,500

-

6,525

16,925

17,159

24,376

42,948

9,725

Net cash (used in) provided by investing activities

-

-

-

-

-

-5,776

-6,920

14,955

-

Net cash provided by investing activities

-36,563

-10,877

-9,970

1,809

8,203

-

-

-

-29,579

Cash flows from financing activities:
Proceeds from sale of future royalties

-

-

-

-

61,184

0

-

-

-

Proceeds from issuance of common stock in equity offerings, net of offering costs

-

-

-

-

-

-

47,943

53,174

34,939

Proceeds from issuance of long-term debt

25,000

-

-

-

-

10,000

14,958

-

19,762

Payment of costs in connection with refinancing of long-term debt

190

-

204

205

215

0

-

-

-

Payment of long-term debt

3,470

7,718

3,514

-

4,534

0

16,345

3,655

5,297

Extinguishment of debt

8,864

-

-

-

-

-

437

-

-

Net proceeds from issuance of common stock through equity plans

-

-

-

-

-

1,869

1,757

246

201

Net cash provided by financing activities

-

-

-

-

-

11,869

47,876

49,765

-

Net proceeds from issuance of common stock in connection with equity financings

1,233

81,525

15,694

-

0

-

-

-

-

Net proceeds from issuance of common stock through equity plans

743

1,218

351

179

3,199

-

-

-

-

Net cash provided by (used in) financing activities

14,452

75,025

12,327

-26

59,634

-

-

-

49,605

Net increase (decrease) in cash and cash equivalents

-73,291

35,073

-27,408

-27,612

47,884

-28,363

40,469

40,138

4,739

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest

1,712

1,667

2,043

1,893

2,115

-

-

-

-

Cash paid for interest

-

-

-

-

-

1,752

1,105

1,632

1,162

Income taxes (refunded) paid

-350

2

2

-55

782

0

-

-

-

Conversion of convertible promissory notes into common stock

-

-

-

-

-

-

-

-

8,137

Issuance of common stock upon cashless exercise of warrants

-

-

-

-

2,544

546

8,428

-

536

Reclassification of warrant liability and call option liability to equity

-

-

-

-

-

-

-

-

906

Issuance of warrants for common stock

-

-

-

-

-

-

1,130

5,828

967

Modification of warrants for common stock

-

-

-

45

100

0

-

-

-

Tenant improvement allowance receivable

-

-

-

-

-

239

-

-

-

Contingent put option liability

-

-

-

-

-

-

334

-

232

Purchases of property and equipment in accounts payable

-

410

222

532

98

182

-

-

-

Leasehold paid with note payable

899

-

-

-

-

-

-

-

-

Transfer of tenant improvement allowance to sublease

242

-

-

-

-

-

-

-

-

Establishment of right-of-use asset due to the adoption of ASU 2016-02

4,730

-

-

-

-

-

-

-

-

Purchases of property and equipment in Accrued liabilities

-

-

-

-

0

23

725

-

-